4//SEC Filing
Donley Matthew Maxwell 4
Accession 0001600620-25-000018
CIK 0001600620other
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 8:56 PM ET
Size
13.3 KB
Accession
0001600620-25-000018
Insider Transaction Report
Form 4
Donley Matthew Maxwell
Chief Operating Officer
Transactions
- Sale
Common Stock
2025-03-03$8.00/sh−65,902$527,216→ 739,456 total - Sale
Common Stock
2025-03-04$7.92/sh−58,991$467,209→ 680,465 total - Award
Common Stock
2025-02-28+82,781→ 669,791 total - Award
Common Stock
2025-03-03+135,567→ 805,358 total - Award
Employee Stock Option (right to buy)
2025-02-28+126,416→ 126,416 totalExercise: $7.55Exp: 2035-02-28→ Common Stock (126,416 underlying)
Footnotes (8)
- [F1]Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement.
- [F2]Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,500 common shares were acquired on May 31, 2024 and 438 common shares were acquired on November 29, 2024.
- [F3]Represents grant of performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2024 and December 31, 2025.
- [F4]Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) related to the February 20, 2024 grant and March 2, 2023 performance award.
- [F5]The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.79 to $8.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F6]Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs related to the March 2, 2022 and March 2, 2023 grants.
- [F7]The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $8.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F8]One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.
Documents
Issuer
Aurinia Pharmaceuticals Inc.
CIK 0001600620
Entity typeother
Related Parties
1- filerCIK 0001636642
Filing Metadata
- Form type
- 4
- Filed
- Mar 3, 7:00 PM ET
- Accepted
- Mar 4, 8:56 PM ET
- Size
- 13.3 KB